16 results about "Novel agents" patented technology

The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and / or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

Provided is a novel cancer microenvironment improving agent capable of improving a cancer microenvironment by microparticles derived from dental pulp-derived stem cells.SOLUTION: It is preferable that the agent is an agent for improving a cancer microenvironment containing microparticles derived from dental pulp-derived stem cells, an agent for improving an antitumor immune response, it is more preferable that the agent improves the cancer microenvironment in a direction in which proliferation of cancer cells can be suppressed by inhibiting the activity of CAF, and it is particularly preferable that the agent improves the cancer microenvironment in a direction in which proliferation of cancer cells can be suppressed by inducing M2-type macrophages into M1-type macrophages, and it is further preferable that the agent is a prophylactic or therapeutic agent for an antitumor immune response, or a method for improving a cancer microenvironment.SELECTED DRAWING: Figure 6

The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

This invention has discovered that the pathogenesis of kidney stones is accompanied by a significant increase in the lactation modification level of histidine at position 147 of ALDOB. Furthermore, when histidine at position 147 is mutated, the lactation modification at position 147 of the mutant amino acid disappears. In vivo experiments show that this mutation can significantly inhibit the accumulation of calcium oxalate crystals in mouse kidneys, preventing the occurrence of kidney stones. Based on this, this invention provides a novel agent and pathway for the prevention and treatment of kidney stones.

The present invention relates to: a pharmaceutical composition for preventing or treating necrotic enteritis, the pharmaceutical composition containing TGF-β1 and FGF2 genes or proteins as active ingredients; and a pharmaceutical preparation and a health functional food that contain the pharmaceutical composition. According to the present invention, TGF-β1 and FGF2, which are known to increase the expression of the CFTR gene, can be used as novel agents for inducing intestinal maturation in premature infants, and various digestive complications such as necrotic enteritis and intestinal absorption disorders, which are intractable diseases, can be treated through the same.

To provide a novel control agent and a novel control method for plant crown gall.SOLUTION: A plant crown gall control agent includes viroid as an active ingredient. Viroid preferably has infection ability to a plant to be controlled, and may be an asymptomatic kind with respect to the plant. The plant may be fruit trees, ornamental flowers, or vegetables.SELECTED DRAWING: None

A novel agent is for treating or preventing a glioma. A marker for malignancy of a brain tumor and a prognostic marker for a brain tumor can be used in a method for determining malignancy of a brain tumor and a method for determining a prognosis for a brain tumor patient. The agent for treating or preventing a glioma can include an HVEM inhibitor as an active ingredient. The marker for malignancy of a brain tumor and the prognostic marker for a brain tumor can each include an HVEM protein or an HVEM gene. The method for determining malignancy of a brain tumor and the method for determining a prognosis for a brain tumor patient can each include measuring an HVEM expression amount in a biological sample of a subject.

Providing a novel agent having an excellent control effect. 【Solution means】Provided are a pyrazole compound represented by formula (1) or a salt thereof, and a novel fungicide containing the same as an active ingredient, particularly a fungicide for agricultural and horticultural use. In the formula, G represents G-1, and G 1 represents C1-C6 alkyl or the like, and R X represents C1-C6 alkyl or the like, and R Y represents a hydrogen atom or the like, and R 2 represents a hydrogen atom or the like, and R 3 represents a hydrogen atom or the like, Z 1 represents E-1 or the like, Z a represents C1-C6 alkyl or the like, Z 2 represents C1-C6 alkyl or the like, m5 represents an integer of 0, 1, 2, 3, 4 or 5, n4 represents an integer of 0, 1, 2, 3 or 4, and v2 represents an integer of 0, 1 or 2. JPEG2026069209000025.jpg24104

An object of the present invention is to provide a novel drug for suppressing progression of osteoarthritis, particularly, a novel drug for suppressing degeneration and / or loss of cartilage.SOLUTION: The present inventors have clarified that when dabigatran etexilate methanesulfonate, which is a thrombin inhibitor having an effect of inhibiting the production of fibrin from fibrinogen, is administered to a patient with knee osteoarthritis, the value indicating the total amount of cartilage matrix degradation products is decreased. That is, the present invention provides an inhibitor of cartilage degeneration in an osteoarthritic joint, the inhibitor containing a fibrin formation inhibitor as an active ingredient, and means for solving the problem.SELECTED DRAWING: None

The invention provides application of danzanoic acid B to prevention and control of beet armyworms, and relates to the technical field of pest prevention and control. The danshinoic acid B can generate a remarkable antifeedant effect on beet armyworms at a certain concentration, plays a role in inhibiting feeding of the beet armyworms, can inhibit growth of beet armyworm larvae to a certain extent and even cause death of the beet armyworm larvae, and can be used as a novel beet armyworm control agent. According to the invention, the defects in the prior art are overcome, the plant-derived extraction component of danzanoic acid B can effectively prevent and treat beet armyworms, and the component is green and safe, reduces environmental pollution, and has a good prospect in the development of a novel agent for preventing and treating beet armyworms.

Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally.

Materials, methods, and systems are provided for proteins comprising a muscle fortifying agent and metabolic modulatory component. The muscle fortifying agent is, for example, a myostatin modulator or the like, an activin type II receptor modulator or the like, or any and each combination thereof. The metabolic component may be an anti-GIPR antibody or fragment thereof and a metabolic modulator. Exemplary metabolic modulators include GLP-1 receptor agonist. In one aspect, the present invention teaches and describes materials, methods, and systems of metabolic modulation, including modulatory agents. For example, the improved materials, methods, and systems of the present invention include novel agents that regulate metabolism in a host. Included are molecules that specifically bind to one or more than one molecule or target, including multispecific molecules, conjugates of a muscle fortifying agent, and for example an additional active metabolic component directly connected or joined via a linker. In particular, the invention includes conjugates or fusions or the like comprising a muscle fortifying agent in combination with a metabolic modulator, including for example a glucagon-like peptide-1 (GLP-1) receptor binding molecule, such as an agonist, and / or an antagonist of the glucose-dependent insulinotropic peptide receptor (GIPR), etc.; and includes nucleic acids and expression vectors encoding the conjugates, recombinant cells thereof, and compositions comprising the conjugates suitable for development and use in hosts. Materials and methods of producing the modulators and various uses are provided.

The present invention aims to provide a novel agent for the prevention and / or treatment of organ fibrosis. [Solution] The present invention is a preventive and / or therapeutic agent for organ fibrosis, comprising mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the culture of mesenchymal stem cells derived from adipose tissue, umbilical cord tissue, or bone marrow tissue. Furthermore, the organ is preferably the kidney.

To provide a novel agent for inhibiting the secretion and / or expression of SASP factors by keratinocytes, as well as an agent for improving keratinocyte metabolism. [Solution] The present invention provides an inhibitor of the secretion and / or expression of SASP factor by keratinocytes, comprising one or more selected from the group consisting of GK2, TA, and 4MSK and their analogs as active ingredients, and a keratinocyte metabolism improvement promoter comprising TA and / or its analog, K2 and / or its analog, and 4MSK and / or its analog.

An object of the present invention is to provide a novel glycation stress inhibitor having an activity of inhibiting glycation stress occurring in vivo.SOLUTION: The glycation stress inhibitor, the glycation reaction inhibitor or the inflammatory reaction inhibitor for inhibiting the inflammatory reaction caused by AGEs contains one or more kinds selected from the group consisting of glycyrrhizic acids, allantoins, azulenes, pyridoxine hydrochloride, hinokitiols, copper chlorophylls, lysozyme chloride and epsilon-aminocaproic acid. Each agent is useful as an external preparation, an agent for oral cavity, a gingival care agent, and a periodontal disease preventive agent.SELECTED DRAWING: None